Karachi November 4 2022: GlaxoSmithKline Consumer Healthcare Pakistan Limited, member of the Haleon Group has lifted the event of force majeure declared on 21 October 2022 for the manufacturing of Panadol Tablets, Panadol Extra Tablets and Children’s Panadol Liquid Range.
“We appreciate the efforts of the Federal Government to revise the prices of Panadol Tablets, Panadol Extra Tablets and Children’s Panadol Liquid Range, which will help the Company to continue to produce everyday healthcare products without gross losses. We are specifically grateful to the Prime Minister, Finance Minister, SAPM for Finance, Health Minister, Health Secretary, CEO DRAP and all other stakeholders in this regard” says Company Chairman Moin Mohajir.
“Although the price revisions granted do not fully mirror the sharp increase in the raw material prices of Paracetamol, we have resumed production in the larger interest of consumers and patients in Pakistan. We look forward to further discussions and engagement with the Federal Government, in due course, to discuss our long-term strategy to provide better everyday health with humanity, and based on trusted science” he added.
The Company resumed the full capacity manufacturing of Panadol Tablets, Panadol Extra Tablets and Children’s Panadol Liquid Range once an agreement was reached with the key Federal Government’s representatives.
“We are grateful for the resolution of this matter and are hopeful for the continued support of all stakeholders to enable the Company to remain fully committed to deliver better everyday health with humanity” says Chief Financial Officer Farhan Muhammad Haroon.
Related Posts
